secwatch.observer — SEC 8-K summary
======================================

Issuer:     INNOVATE Corp. (VATE)
CIK:        0001006837
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001006837-25-000044
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INNOVATE Q1 revenue $274.2M (-13% YoY); net loss widens to $24.8M; MediBeacon TGFR gets FDA approval
--------------------------------------------------------------------------------

- Revenue $274.2M, down 13% YoY; net loss attributable to common $24.8M ($1.89 per share), vs $17.7M loss YoY.
- DBM Global revenue $264.9M (-14% YoY); adjusted backlog $1.4B, added over $500M in new awards.
- MediBeacon TGFR system received FDA approval in Jan to assess kidney function; also NMPA China approval.
- Life Sciences R2 revenue tripled to $3.1M; unit sales up 163% YoY.
- Spectrum revenue $6.2M; signed contract for two new OTA networks; datacasting revenue expected by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006837/000100683725000044/0001006837-25-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006837/000100683725000044/hchc-20250506.htm
  HTML page:      https://secwatch.observer/filing/0001006837-25-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer